An interventional study of Hypofractionated Radiation Therapy and Photon Beam Radiation Therapy in Grade I Meningioma, Grade II Meningioma and Grade III Meningioma, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Emory University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.
Among the 129 studies in Meningioma with a site in United States, this one is the 25th largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2020, is one of 14 with no phase, reaches primary completion later than 34 of the 37 other live ones, and was the 99th registered.
256 studies on the registry are indexed under Meningioma; 86 are open to participants now.
Browse Meningioma studies →27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18+
Eben Rosenthal · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
Joshua Palmer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 55 · Phase 3 6 · Phase 4 2
First in 1992; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 40 across 180 interventional studies indexed under Meningioma.
Median enrollment 30 across the 107 interventional studies, 106 across the 14 observational. Of the 82 that completed or were terminated, 31 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 129 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 2 studies filed under Meningioma — fewer than ten, so there is no comparison to draw.
14 of the studies in Meningioma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03180268Phase 3NRG OncologyObservation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | 2027-06-15 |
| NCT05425004Baptist Health South FloridaCabozantinib for Patients With Recurrent or Progressive Meningioma | 2026-12 |
| NCT04087902Ohio State UniversityLong-Term Longitudinal QoL in Patients Undergoing EEA | 2026-12-31 |
| NCT07150806Joshua PalmerRYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | 2026-12-31 |
| NCT06377371Weill Medical College of Cornell UniversityFeasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 129 studies in Meningioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.
PRIMARY OBJECTIVE:
I. To report 3 year local tumor control of moderately hypofractionated proton or photon therapy for benign intracranial tumors.
SECONDARY OBJECTIVES:
I. To demonstrate feasibility of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors.
II. To report physician reported acute and late toxicity of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
III. To report neurocognitive effects, health related quality of life, and patient reported toxicity for moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
COHORT II: Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant females are excluded. Female of (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. FCBP must agree to use adequate (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
Radiation: Hypofractionated Radiation Therapy · Radiation: Photon Beam Radiation Therapy · Radiation: Proton Beam Radiation Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
Radiation: Hypofractionated Radiation Therapy · Radiation: Photon Beam Radiation Therapy · Radiation: Proton Beam Radiation Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Undergo hypofractionated proton or photon radiation therapy
Also known as: Hypofractionated Radiotherapy, hypofractionation
Undergo hypofractionated proton or photon radiation therapy
Undergo hypofractionated proton or photon radiation therapy
Also known as: PBRT, Proton Radiation Therapy, Radiation, Proton Beam
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
local tumor control
Will assess local tumor control rate. Local tumor control is defined as freedom from progressive disease (PD). Will be calculated as the proportion of patients who did not experience PD within 3-year follow up with 95% binomial proportion confidence interval for the entire population and each cohort independently. The same calculation will be repeated for the entire study population and each cohort separately. Kaplan-Meier method will be used to estimate the local control rates for the entire population and each cohort independently.
Time frame: Up to 3 years since enrollment
Incidence of adverse events
Will be assessed and graded according to Common Terminology Criteria for Adverse Events version 5.0
Time frame: up to 3 years
Neurocognitive effects
Will be summarized by summary statistics.
Time frame: Up to 3 years
Health related quality of life
Will be summarized by summary statistics.
Time frame: Up to 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Dec 2030, 129 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.